Kuick Research Report Gives Insight On 600 CAR T Cell Therapies In Clinical Trials.
Kuick Research Report Gives Insight On 600 CAR T Cell Therapies In Clinical Trials
Global CAR T Cell Therapy Market & Clinical Trials Insight 2028 Report Highlights:
- Research Methodology
- Global CAR T Cell Therapy Market Opportunity > USD 15 Billion
- Global & Regional Market Insight: Current & Market Forecast 2028
- Approved CAR T Cell Therapies Sales Forecast Till 2028
- Emerging In Vivo Induced CAR T Cell Therapies
- CAR T Cell Therapy Manufacturing Cost Analysis
- CAR T Cell Therapy Approval & Reimbursement Scenario By Country
- Patent, Price, Sales Insight On 6 Approved CAR T Cell Therapies
- Insight On More Than 600 CAR T Cell Therapies In Clinical Trials
- CAR T Cell Therapies Clinical Trials Insights by Company, Country & Phase
Download Report: https://www.kuickresearch.com/report-car-t-cell-therapy-market
Chimeric antigen receptor (CAR) T cell therapy is emerging out to be shining star in the immunotherapeutic market. CAR-T cell therapy is a type of immunotherapy that uses modified T-cells to produce CAR on their surface. When these special cells are re-infused into a cancer patient's blood, they target specific antigens and kill tumor cells. In essence, it uses the body's own immune response to attack cancer. Since the entrance of first CAR T cell therapy product in 2017, the market has shown increasing growth rates due to their high efficacy in the management of cancers.
Currently, 7 CAR T cell therapies have been approved globally whereas several others are present in clinical development which is increasingly showing positive clinical results. For instance, Mustang Bio in collaboration with Fred Hutch has developed MB-106 which is novel CD20 directed autologous CAR T Cell therapy. The preliminary results from the phase-I clinical trial in patients with relapsed or refractory B-cell non-Hodgkin lymphomas (B-NHLs) and chronic lymphocytic leukemia (CLL) has demonstrated encouraging results and safety profile in patients. Therefore, it is expected that several new CAR T cell therapies products will enter the global market during the forecast period, thus boosting the growth of market.
Although CAR T cell therapy market is well established in US market, it is still present at very nascent stage in China. Recently in June 2021, China National Medical Products Administration (NMPA) has approved first CAR T cell therapy. Gilead Science has collaborated with Shanghai Fosun Pharmaceutical Group to commercialize Yescarta for the patients with primary mediastinal large B-cell lymphoma, diffuse large B-cell lymphoma, high-grade B-cell lymphoma, and DLBCL from follicular lymphoma. Later in September 2021, NMPA has granted approval to Relmacabtagene autoleucel injection (Carteyva) is an autologous anti-CD19 CAR-T cell immunotherapy products that was independently developed by JW Therapeutics based on a CAR T cell process platform of Juno Therapeutics.
The approval of these drug has marked the beginning of new era of cell therapies in China. It is expected that China will emerge as potential market during the forecast period which is mainly attributed to its increasing focus towards novel cell therapies. Furthermore, several Chinese domestic pharmaceutical companies remain at frontfoot in conducting large number of clinical trials related to CAR T cell therapies. The major companies in Chinese CAR T cell therapy market include Gracell Biotechnologies, SelangBio, Zhejiang Univeristy, Chongqing Precision Biotech, PersonGen BioTherapeutics, and others. As of 2021, SelangBio is sponsoring highest CAR T cell therapy trials in China.
As per our report findings, the global CAR T cell therapy market is expected to surpass US$ 15 Billion by 2028. Several factors including rising geriatric population with increased risk of developing cancer, increasing emphasis on research and development, and large number of ongoing clinical trials are the major factors boosting the growth of market. To date, more than 500 clinical trials are ongoing in the global CAR T cell therapy market which suggests promising future of the market. In addition to this, ongoing clinical trials are also evaluating the role of CAR T cell therapies in combination with other cancer therapies which aim to enhance their efficacy and specificity. All these enlisted factors suggest that CAR T cell therapy has the potential to become one of the most promising cancer therapies during the forecast period.
The global CAR T cell therapy market report involves comprehensive analysis of the various parameters related to this segment along with the analysis of current as well as future market opportunity. The report also analyzes ongoing clinical trials in the market, market drivers, and challenges related to growth of market during the forecast period.
For More Information Related To Report Contact:
Neeraj Chawla
Research Head
Kuick Research
+919810410366